-
1
-
-
27744540889
-
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response
-
Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692-698.
-
(2005)
Diabetes Obes Metab
, vol.7
, pp. 692-698
-
-
Ristic, S.1
Byiers, S.2
Foley, J.3
Holmes, D.4
-
2
-
-
33745903093
-
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
-
Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006;38:423-428.
-
(2006)
Horm Metab Res
, vol.38
, pp. 423-428
-
-
Pratley, R.E.1
Jauffret-Kamel, S.2
Galbreath, E.3
Holmes, D.4
-
3
-
-
33847687205
-
Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebocontrolled, multiple-dose study
-
Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebocontrolled, multiple-dose study. Horm Metab Res. 2007;39:218-223.
-
(2007)
Horm Metab Res
, vol.39
, pp. 218-223
-
-
Dejager, S.1
Razac, S.2
Foley, J.E.3
Schweizer, A.4
-
4
-
-
44949170696
-
Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycemia
-
Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycemia. Diabetes Obes Metab. 2008;10:675-682.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 675-682
-
-
Scherbaum, W.A.1
Schweizer, A.2
Mari, A.3
-
5
-
-
38149137991
-
Characterization of the influence of vildagliptin on model-assessed {beta}-cell function in patients with type 2 diabetes and mild hyperglycemia
-
Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed {beta}-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93:103-109.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 103-109
-
-
Mari, A.1
Scherbaum, W.A.2
Nilsson, P.M.3
-
6
-
-
53549129604
-
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia
-
Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10:1114-1124.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 1114-1124
-
-
Scherbaum, W.A.1
Schweizer, A.2
Mari, A.3
-
7
-
-
34548118796
-
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naïve patients with type 2 diabetes
-
Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naïve patients with type 2 diabetes. Diabet Med. 2007;24:955-961.
-
(2007)
Diabet Med
, vol.24
, pp. 955-961
-
-
Schweizer, A.1
Couturier, A.2
Foley, J.E.3
Dejager, S.4
-
8
-
-
55049142279
-
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: Comparison with metformin
-
Göke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40:892-895.
-
(2008)
Horm Metab Res
, vol.40
, pp. 892-895
-
-
Göke, B.1
Hershon, K.2
Kerr, D.3
-
9
-
-
71849095372
-
Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes
-
Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res. 2009;41:905-909.
-
(2009)
Horm Metab Res
, vol.41
, pp. 905-909
-
-
Foley, J.E.1
Sreenan, S.2
-
10
-
-
41749106662
-
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: A 24-week, double-blind, randomized trial
-
Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25:435-441.
-
(2008)
Diabet Med
, vol.25
, pp. 435-441
-
-
Pan, C.1
Yang, W.2
Barona, J.P.3
-
11
-
-
33846694046
-
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial
-
Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30:217-223.
-
(2007)
Diabetes Care
, vol.30
, pp. 217-223
-
-
Rosenstock, J.1
Baron, M.A.2
Dejager, S.3
-
12
-
-
65549109984
-
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus
-
Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diab Obes Metab. 2009;11:571-578.
-
(2009)
Diab Obes Metab
, vol.11
, pp. 571-578
-
-
Rosenstock, J.1
Niggli, M.2
Maldonado-Lutomirsky, M.3
-
13
-
-
38149096290
-
Effects of the DPP-4 inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
-
Rosenstock J, Foley JE, Rendell M, et al. Effects of the DPP-4 inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31:30-35.
-
(2008)
Diabetes Care
, vol.31
, pp. 30-35
-
-
Rosenstock, J.1
Foley, J.E.2
Rendell, M.3
-
14
-
-
33846905487
-
Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
-
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132-138.
-
(2007)
Diabetes Res Clin Pract
, vol.76
, pp. 132-138
-
-
Pi-Sunyer, F.X.1
Schweizer, A.2
Mills, D.3
Dejager, S.4
-
15
-
-
67649933635
-
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, double-blind, randomized trial
-
Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11:804-812.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 804-812
-
-
Schweizer, A.1
Dejager, S.2
Bosi, E.3
-
16
-
-
9444285818
-
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
-
Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-2880.
-
(2004)
Diabetes Care
, vol.27
, pp. 2874-2880
-
-
Ahrén, B.1
Gomis, R.2
Standl, E.3
-
17
-
-
34147093268
-
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
-
Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890-893.
-
(2007)
Diabetes Care
, vol.30
, pp. 890-893
-
-
Bosi, E.1
Camisasca, R.P.2
Collober, C.3
-
18
-
-
58149330590
-
Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
-
Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157-166.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 157-166
-
-
Ferrannini, E.1
Fonseca, V.2
Zinman, B.3
-
19
-
-
77955048324
-
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglyceamic risk compared with glimepiride, with no weight gain: Results from a 2-year study
-
Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglyceamic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-789.
-
(2010)
Diabetes Obes Metab
, vol.12
, Issue.9
, pp. 780-789
-
-
Matthews, D.R.1
Dejager, S.2
Ahren, B.3
-
20
-
-
77949356196
-
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study
-
Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diab Med. 2010;27(3):318-326.
-
(2010)
Diab Med
, vol.27
, Issue.3
, pp. 318-326
-
-
Filozof, C.1
Gautier, J.F.2
-
21
-
-
37349054435
-
Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: A 24-week, randomized, double-blind study
-
Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10:82-90.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 82-90
-
-
Bolli, G.1
Dotta, F.2
Rochotte, E.3
Cohen, S.E.4
-
22
-
-
65549131200
-
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
-
Bolli G, Dotta F, Colin L, et al. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009;11:589-595.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 589-595
-
-
Bolli, G.1
Dotta, F.2
Colin, L.3
-
23
-
-
67949105103
-
Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
-
Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res. 2009;41:368-373.
-
(2009)
Horm Metab Res
, vol.41
, pp. 368-373
-
-
Goodman, M.1
Thurston, H.2
Penman, J.3
-
24
-
-
77957751894
-
Effect of metformin as add-on therapy to a low dose metformin
-
Filozof C, Schwartz S, Foley JE. Effect of metformin as add-on therapy to a low dose metformin. World J Diabetes. 2010;1:19-26.
-
(2010)
World J Diabetes
, vol.1
, pp. 19-26
-
-
Filozof, C.1
Schwartz, S.2
Foley, J.E.3
-
25
-
-
65449135133
-
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
-
Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11:506-515.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 506-515
-
-
Bosi, E.1
Dotta, F.2
Jia, Y.3
Goodman, M.4
-
26
-
-
33846828660
-
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebocontrolled study
-
Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebocontrolled study. Diabetes Obes Metab. 2007;9:166-174.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 166-174
-
-
Garber, A.J.1
Schweizer, A.2
Baron, M.A.3
-
27
-
-
33846827085
-
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes
-
Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-185.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 175-185
-
-
Rosenstock, J.1
Baron, M.A.2
Camisasca, R.P.3
-
28
-
-
54249106294
-
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
-
Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10:1047-1056.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 1047-1056
-
-
Garber, A.J.1
Foley, J.E.2
Banerji, M.A.3
-
29
-
-
34247874561
-
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
-
Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148-1155.
-
(2007)
Diabetologia
, vol.50
, pp. 1148-1155
-
-
Fonseca, V.1
Schweizer, A.2
Albrecht, D.3
-
30
-
-
47049084841
-
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
-
Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40:427-430.
-
(2008)
Horm Metab Res
, vol.40
, pp. 427-430
-
-
Fonseca, V.1
Baron, M.2
Shao, Q.3
Dejager, S.4
|